




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Hypertension</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=f68125ba-f38e-40e5-aa3d-65a1eea96f8e</link>
        <description>Clinical Topic Feed: Hypertension</description>
        <language>en</language>

        

                <item>
                    <title>FDA Update: Agency Approves Baxdrostat to Treat Adults With HTN</title>
<link>/Latest-in-Cardiology/Articles/2026/05/19/15/49/FDA-Update-Agency-Approves-Baxdrostat-to-Treat-Adults-With-HTN</link>                    <description>The U.S. Food and Drug Administration (FDA) has approved baxdrostat, a first-in-class oral aldosterone synthase inhibitor, as an add-on therapy for hypertension in adults whose blood pressure (BP) is not adequately controlled with other antihypertensive medications.</description>
                    <pubdate>1779205980000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACCEL Lite: THRIVE Food is Medicine Pilot Trial: Addressing Hypertension Through Produce Prescriptions</title>
<link>/Latest-in-Cardiology/Articles/2026/05/18/14/48/accel-lite-19may2026</link>                    <description>In this episode, Alison L. Bailey, MD, FACC and Bunmi Ogungbe, BSN, MPH, PhD discuss &#226;€œTHRIVE Food is Medicine Pilot Trial: Addressing Hypertension through Produce Prescriptions&#226;€.</description>
                    <pubdate>1779204600000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Rising HDP Rates in the US; BP Monitoring Across the Lifespan</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/05/11/15/12/Rising-HDP-Rates-in-the-US</link>                    <description>The rate of new-onset hypertensive disorders of pregnancy (HDP) in the U.S. increased significantly from 2016 to 2024 across all racial and ethnic groups, according to a brief JACC report &#226;€“ the importance of which is further echoed in a longer systematic review of blood pressure (BP) monitoring across a patient&#39;s lifespan published in JACC&#39;s May 12 hypertension focus issue.</description>
                    <pubdate>1778688120000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Hypertension Risk From Low-Level PM Exposure</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/05/04/11/24/Hypertension-Risk-From-Low-Level-PM-Exposure</link>                    <description>Long-term exposure to fine particulate matter &#226;‰&#164;2.5 &amp;mu;m in diameter (PM2.5), which is below current regulatory thresholds in the U.S., may contribute to increased hypertension risk, according to a national cohort study published April 15 in JACC.</description>
                    <pubdate>1778087340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>&#226;€&#175;Eagle&#226;€™s Eye View: PCI Vs. CABG In Patients With Unprotected Left Main CAD: NOBLE Study </title>
<link>/Latest-in-Cardiology/Articles/2026/05/06/13/43/eagles-eye-view-06may2026</link>                    <description>In this week&#226;€™s View, Dr. Eagle&#226;€&#175;looks at the NOBLE trial evaluating whether percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) is best for patients with unprotected left main coronary artery disease (CAD).</description>
                    <pubdate>1778075040000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>JACC in a Flash | Electronic Alerts For Managing AS, MR; More</title>
<link>/Latest-in-Cardiology/Articles/2026/05/01/01/JACC-in-a-Flash</link>                    <description>Featured topics and Editors&#39; Picks from all of ACC&#39;s JACC Journals.</description>
                    <pubdate>1777637400000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Journal Wrap | Evolocumab Cuts Risk in Absence of ASCVD: Sotatercept For CpCPH, HFpEF</title>
<link>/Latest-in-Cardiology/Articles/2026/05/01/01/Journal-Wrap</link>                    <description>The hottest research from various peer-reviewed journals &#226;€“ handpicked weekly by the ACC.</description>
                    <pubdate>1777637340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Preventing Pregnancy-Related CVD and Maternal Mortality in the US</title>
<link>/Latest-in-Cardiology/Articles/2026/04/30/10/29/Preventing-Pregnancy-Related-CVD</link>                    <description>A new report from the National Academies of Sciences, Engineering, and Medicine calls for &quot;stronger clinical preventive services, better follow-up after delivery, and improved care coordination across the reproductive life course&quot; to better manage cardiovascular disease risk in pregnant and postpartum patients...</description>
                    <pubdate>1777573140000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Heart Failure Trials Featured at ACC.26</title>
<link>/Latest-in-Cardiology/Articles/2026/04/27/19/07/Heart-Failure-Trials-Featured-at-ACC26</link>                    <description>ACC.26 featured several late-breaking heart failure clinical trials, including two focused on subgroups of heart failure that until now had limited data to guide therapies.</description>
                    <pubdate>1777460220000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Implications of ACC.26 Prevention Trials For Future Guidelines</title>
<link>/Latest-in-Cardiology/Articles/2026/04/27/19/07/Implications-of-ACC26-Prevention-Trials-For-Future-Guidelines</link>                    <description>The VESALIUS-CV trial primary prevention analysis was a prespecified evaluation of use of evolocumab in 3,655 trial participants who had elevated LDL cholesterol (LDL-C) values but no evidence of significant atherosclerotic cardiovascular disease (ASCVD), defined as no prior revascularization, no arterial stenosis...</description>
                    <pubdate>1777391340000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>